One of the major challenges is correctly identifying patients who would benefit from EV therapy, as the expression of Nectin-4 at the level of the primary tumour and metastases determines the amount of the drug that can reach tumour cells [70]. This evidence concerns the gene NECTIN4 and neoplasm.